Citi analyst Filippo Falorni resumed coverage of Kenvue with a Neutral rating and $21 price target following the completion of a secondary offering on May 14. The firm sees an “unclear” near-term outlook for the company, driven by difficult Q2 comparisons, a slow start to the allergy season, Neutrogena struggling to recover share, and uncertainty on its China recovery.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE: